Physician profile
Patrick C Hayes
NPI 1619052461
$837,094.71
in general payments reported to CMS, 2019-2025
18 companies · $168K in 2025
The $168K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91K · 2020: $32K · 2021: $99K · 2022: $131K · 2023: $182K · 2024: $135K · 2025: $168K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $254K · Consulting Fee: $115K · Honoraria: $68K · Travel and Lodging: $35K · Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $253,865.00 |
| Consulting Fee | $115,126.50 |
| Honoraria | $68,266.00 |
| Travel and Lodging | $35,106.86 |
| Food and Beverage | $12,303.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $291,396.50 | 2020-2025 | Ingrezza |
| Alkermes, INC. | $287,993.53 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Axsome Therapeutics, INC. | $181,922.43 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $32,534.11 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $30,910.95 | 2023-2025 | Uzedy, Austedo Xr |
| Eisai INC. | $11,485.66 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $270.03 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $139.48 | 2021-2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $109.11 | 2020-2023 | Trintellix |
| Vanda Pharmaceuticals INC. | $101.64 | 2019-2020 | |
| Indivior INC. | $64.46 | 2019-2022 | |
| Noven Therapeutics, LLC | $58.24 | 2020-2023 | Xelstrym |
| Corium, LLC | $21.12 | 2025 | Azstarys |
| Abbvie INC. | $19.93 | 2021 | |
| Avanir Pharmaceuticals, INC. | $19.21 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $18.81 | 2022 | |
| Neuronetics, INC. | $15.35 | 2023 | Neurostar Tms Therapy System |
| Supernus Pharmaceuticals, INC. | $14.15 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Hayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.